
CLAIMS

1. A Compound according to Formula I



I

wherein R1-R7 are selected as follows:

a) R1 is a radiolabelled group comprising at least one isotope selected from the group consisting of $^{11}CH_3$, $-CH_2{}^{11}CH_3$, $-{}^{11}CH_2CH_3$, $-CH_2CH_2{}^{11}CH_3$, $-{}^{11}CH_2CH_2CH_3$, $-{}^{11}CH_2CH_2CH_2CH_3$, $-CH_2CH_2CH_2{}^{11}CH_3$, $-CH_2CH_2{}^{18}F$, $-CH_2CH_2CH_2{}^{18}F$, $-CH_2CH_2CH_2CH_2{}^{18}F$; R3, R4, and R5 are H and R7 is CH_3 and R2 is H and R6 is CH_3; or a salt or a hydrate form of the compound.

2. The compound according to claim 1 wherein R1 is $^{11}CH_3$ ([^{11}C]methyl).

3. The compound according to claim 1, wherein the compound is 5,8-dimethyl-2-[2-([^{11}C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine.

4. Use of a compound according to any of claims 1-3 as a PET ligand.

5. The use according to claim 4 for determination of the binding occupancy of a PDE10A enzyme ligand at the PDE10A enzyme.

~~6. A method for the preparation of a compound according enzyme. to any of claim 1 to 3.~~